A phase II study of high-dose cetuximab plus irinotecan in colorectal cancer patients with KRAS-wild type tumors who progressed on prior standard dose cetuximab and irinotecan.
Ahmad Ali Fora
No relevant relationships to disclose
Jeanne A McMahon
No relevant relationships to disclose
Greg Wilding
No relevant relationships to disclose
Adrienne E. Groman
No relevant relationships to disclose
Wen Wee Ma
No relevant relationships to disclose
Karen S. Romano
No relevant relationships to disclose
Marwan Fakih
No relevant relationships to disclose